MARKET

ABIO

ABIO

Arca Biopharma Inc
NASDAQ
3.285
-0.025
-0.76%
After Hours: 3.320 +0.035 +1.07% 18:29 07/19 EDT
OPEN
3.250
PREV CLOSE
3.310
HIGH
3.300
LOW
3.160
VOLUME
37.46K
TURNOVER
0
52 WEEK HIGH
4.490
52 WEEK LOW
1.560
MARKET CAP
47.66M
P/E (TTM)
-7.9061
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABIO last week (0708-0712)?
Weekly Report · 6d ago
Citizens And 4 Other Stocks Under $5 Insiders Are Buying
When insiders purchase or sell shares, it indicates confidence or concern around the company's prospects. The Dow Jones index closed higher by more than 200 points on Friday. Recent notable insider transactions for penny stocks include ARCA biopharma, Douglas Elliman and Willamette Valley Vineyards.
Benzinga · 6d ago
Weekly Report: what happened at ABIO last week (0701-0705)?
Weekly Report · 07/08 12:01
Weekly Report: what happened at ABIO last week (0624-0628)?
Weekly Report · 07/01 12:02
Weekly Report: what happened at ABIO last week (0617-0621)?
Weekly Report · 06/24 12:12
Weekly Report: what happened at ABIO last week (0610-0614)?
Weekly Report · 06/17 12:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Calidi Biotherapeutics shares rose 29.7% to $0.25 during Monday's pre-market session. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% during the session. Co-Diagnostics stock moved upwards by 14.07%. Sunshine Biopharma and Skye Bioscience were among the losers.
Benzinga · 06/10 12:06
Weekly Report: what happened at ABIO last week (0603-0607)?
Weekly Report · 06/10 12:03
More
About ABIO
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Webull offers Arca Biopharma Inc stock information, including NASDAQ: ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.